GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antengene Corp Ltd (HKSE:06996) » Definitions » Equity-to-Asset

Antengene (HKSE:06996) Equity-to-Asset : 0.71 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Antengene Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Antengene's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$1,254.98 Mil. Antengene's Total Assets for the quarter that ended in Dec. 2023 was HK$1,770.38 Mil. Therefore, Antengene's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.71.

The historical rank and industry rank for Antengene's Equity-to-Asset or its related term are showing as below:

HKSE:06996' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.97   Med: 0.75   Max: 0.95
Current: 0.71

During the past 6 years, the highest Equity to Asset Ratio of Antengene was 0.95. The lowest was -1.97. And the median was 0.75.

HKSE:06996's Equity-to-Asset is ranked better than
54.69% of 1556 companies
in the Biotechnology industry
Industry Median: 0.67 vs HKSE:06996: 0.71

Antengene Equity-to-Asset Historical Data

The historical data trend for Antengene's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antengene Equity-to-Asset Chart

Antengene Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial -0.73 0.95 0.94 0.80 0.71

Antengene Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.94 0.91 0.80 0.84 0.71

Competitive Comparison of Antengene's Equity-to-Asset

For the Biotechnology subindustry, Antengene's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Antengene's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Antengene's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Antengene's Equity-to-Asset falls into.



Antengene Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Antengene's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=1254.984/1770.376
=0.71

Antengene's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=1254.984/1770.376
=0.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Antengene  (HKSE:06996) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Antengene Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Antengene's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Antengene (HKSE:06996) Business Description

Traded in Other Exchanges
N/A
Address
1065 West Zhongshan Road, Suites 1206-1209, Block B, Zhongshan SOHO Plaza, Changning District, Shanghai, CHN
Antengene Corp Ltd is a clinical-stage biopharmaceutical company focused on oncology medicines. The company produces drugs such as selinexor, eltanexor, verdinexor, and other products. It also engages in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics for the treatment of hematologic malignancies and solid tumors. Geographically it operates in China and other regions.
Executives
Jay Mei 2023 Grat 2201 Interest of corporation controlled by you
Mei Jay 2201 Interest of corporation controlled by you
Begonia Investment Ltd. 2101 Beneficial owner
Qiming Corporate Gp V, Ltd.
The Core Trust Company Limited 2301 Trustee
Tct (bvi) Limited 2501 Other
Fountainvest China Capital Partners Gp3 Ltd. 2201 Interest of corporation controlled by you
Fountainvest China Capital Partners Fund Iii, L.p. 2201 Interest of corporation controlled by you
Fmr Llc 2201 Interest of corporation controlled by you
Fidelity Investment Trust 2101 Beneficial owner
Jay Mei 2020 Grat 2201 Interest of corporation controlled by you
Meiland Pharma Tech Spc
Boyu Capital Group Holdings Ltd 2201 Interest of corporation controlled by you
Boyu Capital General Partner Iii, Ltd
Boyu Capital General Partner Iii, L.p.

Antengene (HKSE:06996) Headlines

No Headlines